Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Trial Profile

Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms JPMS-CTEPH
  • Sponsors Bayer

Most Recent Events

  • 26 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 20 Apr 2023 Status changed from recruiting to active, no longer recruiting.
  • 12 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top